share_log

BioHarvest Launches VINIA SuperFood Functional Tea Line

BioHarvest Launches VINIA SuperFood Functional Tea Line

BioHarvest推出VINIA SuperFood功能茶系列
newsfile ·  11/25 21:30

Incremental Product Launch Addresses $3.3 Billion North American Functional Tea Market Opportunity with First SuperFood Tea Infused with Piceid Resveratrol

以第一款以白藜蘆醇爲特色的超級食品茶解決33億美國功能茶市場機遇的增量式產品推出

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 25, 2024) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of its highly anticipated VINIA infused teas - a line of SuperFood functional teas that deliver the same clinically validated benefits as the successful VINIA supplements. This launch further demonstrates the potential of VINIA's lifetime value across multiple consumer verticals.

溫哥華,英屬哥倫比亞和以色列 Rehovot - (新聞稿社 - 2024年11月25日) - BioHarvest Sciences Inc.(納斯達克股票代碼:BHST)(CSE股票代碼:BHSC)(FSE股票代碼:8MV0)(「BioHarvest」或「公司」)是一家開創性利用其專利植物合成技術平台的公司,今天宣佈推出備受期待的VINIA浸泡茶 - 一系列可交付與成功的VINIA補充品相同的經臨床驗證的功能茶。這次推出進一步展示了VINIA在多個消費者垂直領域中的生命週期價值潛力。

Tens of thousands of subscribers take VINIA daily to improve blood flow as a supplement in capsule form or through VINIA Superfood coffee, which increases their dilation of arteries, improving blood flow and enhancing their physical energy and mental alertness. Now consumers can experience those same blood flow improvements together with a cup of great tasting VINIA Superfood Tea, featuring four premium blends: Black Tea, Green Tea, Matcha Green Tea and Cranberry Hibiscus Herbal Tea.

成千上萬的訂閱用戶每天以膠囊形式或通過可以增加動脈擴張、改善血液流動並增強身體活力和精神警覺性的VINIA超級食品咖啡作爲補品來服用VINIA。現在消費者可以通過一杯美味的VINIA超級食品茶體驗相同的血液流動改善,該茶包括四種優質混合:紅茶、綠茶、抹茶綠茶和蔓越莓木槿茶。

BioHarvest's VINIA SuperFood Infused Teas - which contain the equivalent piceid resveratrol contained in one capsule of VINIA - deliver superior science, efficacy and taste. Third party blind taste testing shows BioHarvest's VINIA infused teas outperformed leading English Breakfast and Green Tea brands. All the tea used in the VINIA SuperFood Infused Teas lineup are sourced from Rainforest Alliance certified farms.

BioHarvest的VINIA超級食品浸泡茶 - 其中包含相當於一顆VINIA膠囊中含有的白藜蘆醇 - 提供優越的科學、有效性和口感。第三方盲品測試顯示,BioHarvest的VINIA浸泡茶勝過領先的英式早餐茶和綠茶品牌。VINIA超級食品浸泡茶系列中使用的所有茶葉均來自雨林聯盟認證農場。

Ilan Sobel, Chief Executive Officer of BioHarvest, said: "Following the successful launch of our VINIA Capsules and VINIA SuperFood Coffee, we are now extending VINIA's circulatory health benefits to the tea category, executing our 'VINIA Inside' strategy to meet consumer demand across multiple VINIA delivery mechanisms.

BioHarvest的首席執行官Ilan Sobel表示:“在成功推出VINIA膠囊和VINIA超級食品咖啡後,我們現在正在將VINIA的循環健康益處延伸到茶類別,執行我們的『VINIA內部』策略,以滿足跨多種VINIA傳遞機制的消費者需求。

"We believe this new VINIA Superfood Functional Tea line will be a disruptor in the $3.3B functional tea market in North America[1], bringing unique benefits to the category with a product that is simply superior from a taste, science and efficacy perspective. From a financial perspective, the 'VINIA Inside' strategy has been designed to capture more gross profit dollars per unit while addressing a highly incremental, younger consumer base."

「我們相信這款新型VINIA超級食品功能茶線將成爲北美33億功能茶市場的顛覆者[1],爲該類別帶來獨特優勢,產品從口感、科學和效用角度而言簡直是卓越無比。從財務角度而言,『VINIA內部』戰略旨在每單位獲得更多毛利潤美元,並滿足高度增量的年輕消費者群體的需求。」

BioHarvest will launch its VINIA infused tea line across major channels starting Saturday, December 7th, following a VIP launch commencing today for select existing VINIA subscribers.

BioHarvest將於12月7日星期六開始在主要渠道推出其注入VINIA的茶系列,今天起將爲部分現有VINIA訂閱用戶進行VIP發佈活動。

1Market Research Future - Global Functional Tea Market Overview - 2023

Market Research Future - 全球功能茶市場概況 - 2023

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc.簡介

BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit .

BioHarvest Sciences Inc. (納斯達克: BHST) (cse: BHSC) (FSE: 8MV) 是植物合成領域的領導者,利用其擁有專利的技術平台在植物中培育活性成分,無需培育底層植物。BioHarvest正在利用其植物合成技術開發下一代基於科學且經臨床證實的治療解決方案,涵蓋兩大主要業務板塊:作爲代表尋求複雜分子的客戶的合同開發和生產組織 (CDMO),以及作爲擁有營養保健及健康產品的專有權專家,包括膳食補充劑。欲了解更多信息,請訪問 。

Forward-Looking Statements

前瞻性聲明

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Launching new products is subject to risks and uncertainties including the risk that the market will not accept the product or that government approvals required for sale or import of the products will not be obtained. There is never an assurance that any product set will successfully disrupt established product categories. There is no assurance that the Company will maintain or improve current financial performance, as revenues and margins are dependent on a combination of factors such as supply chain efficiencies, input cost stability, marketing efficiencies and uncertain consumer preferences. There is no guarantee that higher prices charged for new products will equate to higher profit margins or higher gross dollar profit per unit. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

本新聞稿中所載資料可能包含基於管理層目前估計、信仰、意圖和期望的前瞻性聲明,受到可能導致實際結果與前瞻性聲明描述不符的一系列風險和不確定性的影響。推出新產品涉及風險和不確定性,包括市場可能不接受產品,或產品銷售或進口所需的政府批准可能無法獲得的風險。無法保證任何產品組合將成功顛覆既定的產品類別。公司將保持或提高目前的財務業績,收入和利潤率將取決於一系列因素,如供應鏈效率、輸入成本穩定性、市場推廣效率和不確定的消費者偏好。對新產品收取較高價格並不能保證會帶來更高利潤率或更高的單位毛利潤。所有前瞻性聲明都有一定的不確定性,實際結果可能受到多種我們無法控制的重要因素的影響。讀者不應過分依賴前瞻性聲明。BHSC不打算通過除定期管理討論和分析披露以外的方式更新前瞻性聲明。

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

加拿大證券交易所及其規定服務供應商對本聲明的充分性或準確性不承擔任何責任。

This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibility for its contents.

此新聞稿已由VP Investor Relations戴夫·瑞安審查並批准,他對其內容負責。

BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
+1 (604) 622-1186
info@bioharvest.com

BioHarvest的公司聯繫方式:
Dave Ryan, 投資者關係副總裁
+1 (604) 622-1186
info@bioharvest.com

Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us

投資者關係聯繫人:
Lucas A. Zimmerman
常務董事
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論